Illumina (ILMN) CEO Jay Flatley tells Bloomberg that while the fiscal cliff will affect a third...


Illumina (ILMN) CEO Jay Flatley tells Bloomberg that while the fiscal cliff will affect a third of the gene-sequencing company's customers, "it's going to probably be pretty short-lived." Flatley also says that Roche going public in January with its $6.7B offer for Illumina stopped the board from properly discussing the offer and possibly put paid to the deal.

From other sites
Comments (2)
  • mikevr
    , contributor
    Comment (1) | Send Message
     
    Hugely misleading information. Flatley & the board adopted a poison pill strategy against Roche (illegal in Europe where known to be primarily used to fatten board member purses). Roche was non-receptive to this ploy. The CEO and the board had plenty of time "to properly discuss".

     

    Critique #1: Hiostorically, Flatley selected and kept only board members favorable to managment [over share holders.]

     

    Critue #2: Disingenuousness: Flatley claimed ILMN, [like Roche has already done] would develop DNA tests predictive of medical diseases. Flatley has done nothing here. There are no new DNA applications.
    19 Sep 2012, 02:58 PM Reply Like
  • parkavemom
    , contributor
    Comment (1) | Send Message
     
    Learn how to spell or stop typing when your drinking and make a direct point.

     

    As far as I know from scientists in the field, Illumina still holds the high standard above the other companies.
    21 Sep 2012, 12:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs